CNS metastases in breast cancer patients: prognostic implications of tumor subtype
CNS metastases in breast cancer patients: prognostic implications of tumor subtype
复制标题
DOI：
10.1007/s12032-014-0400-2
复制
发表时间：
2015-01-01
期刊：
影响因子：
3.4
通讯作者：
Grischke, E.
中科院分区：
文献类型：
--
作者：
Bachmann, C.;Schmidt, S.;Grischke, E.
乳腺癌脑转移（BM）的发展导致生存率有限。治疗选择有限。关于BM的危险因素和预后重要性的数据较少。目的根据肿瘤亚型探讨BM诊断后中枢神经系统转移和预后的预测因素。根据病历，对80例在图宾根大学妇科接受治疗的原发性非转移性可手术乳腺癌患者进行回顾性分析，这些患者在随访期间发生BM。评估临床病理参数及其预后影响。淋巴结受累（40%）、ER/PR阴性（53.75 vs. 61.25%）、三阴性（28.75%）和HER 2+状态（40%）与BM相关。乳腺癌患者的BM导致生存期缩短。在HER 2阴性和三阴性的脑转移性乳腺癌患者中，与HER 2阳性和非三阴性患者相比，检测到BM后患者的生存期显著缩短（p = 0.001; p = 0.03）。BM的风险因亚型而异。了解转移瘤的生物学可以帮助将患者分类为医学上有用的类别，并为个体患者定制治疗方案。需要前瞻性临床试验来评估无症状BM筛查和三阴性患者治疗的潜在作用。
Development of brain metastases (BM) in breast cancer leads to limited survival. The therapeutical options are limited. There are less data about the risk factors and prognostic importance in BM. Objective is to investigate predictors of central nervous system metastases and outcome after diagnosis of BM according to tumor subtype. Based on medical records, 80 consecutive patients with primary non-metastatic operable breast cancer, treated at Department of Gynecology, University of Tu "bingen, and who developed BM during follow-up, were retrospectively analyzed. Clinicopathological parameters and their prognostic impact were evaluated. A node involvement (40 %), ER/PR negative (53.75 vs. 61.25 %), triple negative (28.75 %) and HER2+ status (40 %) were associated with BM. BM in breast cancer patients lead to a shortened survival. In cerebral metastatic breast cancer patients with HER2-negative and triple-negative, patients had significant shorter survival after detection of BM compared with HER2-positive and non-triple-negative patients (p = 0.001; p = 0.03). Risk of BM varies significantly by subtype. Understanding the biology of metastases can help categorize patients into prognostically useful categories and tailor treatment regimens for individual patients. Prospective clinical trials would be required for evaluating the potential role of screening for asymptomatic BM and of treatment of triple-negative patients.